AKVA group ASA
AKVA group ASA hereby invites you to the presentation of the Q4 2020 financial results, which will take place as follows:
Time: Friday 12 March 2021 at 10:00 CET
Webcast: https://channel.royalcast.com/landingpage/hegnarmedia/20210312_1/
A recorded version of the presentation will be available after the live stream is concluded.
The presentation will be held in English and is open to all interested parties.
Dated: 1 March 2021
AKVA group ASA
Web: www.akvagroup.com
CONTACTS:
Knut Nesse | Chief Executive Officer |
Phone: | +47 51 77 85 00 |
Mobile: | +47 91 37 62 20 |
E-mail: | knesse@akvagroup.com |
Ronny Meinkøhn | Chief Financial Officer |
Phone: | +47 51 77 85 00 |
Mobile: | +47 98 20 67 76 |
E-mail: | rmeinkohn@akvagroup.com |
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom